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Metastases are the hallmark of cancer. This event is in direct relationship with the ability of cancer cells to leave the tumor mass
and travel long distances within the bloodstream and/or lymphatic vessels. Glioblastoma multiforme (GBM), the most frequent
primary brain neoplasm, is mainly characterized by a dismal prognosis. The usual fatal issue for GBM patients is a consequence of
local recurrence that is observed most of the time without any distant metastases. However, it has recently been documented that
GBMcells could be isolated from the bloodstream in several studies.This observation raises the question of the possible involvement
of glioblastoma-circulating cells in GBM deadly recurrence by a “homingmetastasis” process.Therefore, we think it is important to
review the already known molecular mechanisms underlying circulating tumor cells (CTC) specific properties, emphasizing their
epithelial to mesenchymal transition (EMT) abilities and their possible involvement in tumor initiation. The idea is here to review
these mechanisms and speculate on how relevant they could be applied in the forthcoming battles against GBM.
1. Introduction
Circulating tumor cells (CTC) are the main required sub-
strate for cancer to spread and extend metastases. These
cells originally come from the primary tumor and reach the
vascular compartment. CTC are then able to leave the cir-
culation, migrate through the conjunctive tissue of different
organs, and proliferate to formmetastases. It remains unclear
whether CTC are able to go back to the primary tumor
site, specifically after therapeutic treatment, and therefore to
participate to tumor recurrence.
In fact, it has been suggested that a very small proportion
of CTC can form metastases. This subpopulation of cells
is called circulating tumor stem cells (CTSC). Indeed, this
subpopulation is thought to be self-renewing, multipotent,
and capable of tumor initiation [1]. Up to now, different
hypotheses try to explain their presence in the peripheral
blood, involving several mechanisms to cross the vascular
barrier. Because of their properties, these cells are of high
interest to counteract the evolution of the disease and
metastases formation. This review aims to better understand
the biology of these CTSC with a particular focus on
glioblastoma multiforme, a grade IV malignant brain tumor
characterized by a dead-end prognosis, systematic relapses,
and rare metastases.
2. Origins, Circulation, and Destinations of
Circulating Tumor Stem Cells (CTSC)
CTC come from the initial tumor or from eventual metas-
tases. In the tumor mass, less than 5% of malignant cells
[2] are known to preserve a self-renewal potential through
multiple generations and are able to create a new tumor.
These are called cancer stem cells (CSC). Classically, CSC
are defined by three major in vitro properties: formation of
spherical colonies in culture suspension, differential levels
and patterns of surface markers, and increased survival after
radiation or chemotherapeutic treatment [3–7]. Moreover, in
experimental models, those CSC are the only tumor cells
able to initiate the development of new tumors in hetero-
topic or homotopic xenotransplantation experiments. These
CSC present high tolerance to the lethal environment, host
defense and growth-suppression factors thanks to immune
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mediators, cell cycle checkpoints, and DNA damage control
pathways [8].
From this, different hypotheses attempted to elucidate the
presence of CSC in the blood or circulating tumor stem cells
(CTSC). CSC can use a normalmorphogenetic process called
EpithelialMesenchymal Transition (EMT) [9] tomodify their
features in order to escape the tissue of origin and to migrate
towards the vascular compartment [10]. Liu and collaborators
recently demonstrated that differentiated tumor cells acquire
migratory abilities due to the development of EMT pathways
[11] (Figure 1(a)). The intravasation is finally possible by
the secretion of enzymes, such as serine/cysteine proteases,
matrix metalloproteases (MMP) or disintegrins, and other
metalloproteases (ADAMS), in order to degrade the basal
membrane of blood vessels [12]. The presence of tumor-
associatedmacrophages (TAMs), especially in hypoxic region
of tumor [13], seems indeed to facilitate the intravasation
process, maybe via secretion of MMP-9 [14].
Once in the bloodstream, most of the CTC, including
CSC, undergo an important selection by shear forces or
natural killer (NK) cells from the immune system [15]. How-
ever, CTC can aggregate to cellular elements [16] or platelets
[17] and express several receptor tyrosine kinases (RTK),
antiapoptotic molecules and invasion signaling components
[16, 18]. CTC in this way are able to avoid not only the
immune response but also anoikis [18]. To extravasate, CTC
use diapedesis to escape the vascular compartment [19].
Then, CTC that present mesenchymal features can inverse
their transition and then recover their epithelial phenotype
of origin via a process called Mesenchymal to epithelial
transition (MET). Some CTC finally become quiescent in
a new and favorable environment and can later on fully
participate to cancer relapses (Figure 1(e)).
3. EMT Conditions and Molecular Regulation
If CTC are the substrate, EMTmight be a necessary condition
for cancer dissemination. EMT is indeed thought to be
the program that cancer cells follow to acquire metastatic
features. This substantially simplifies our conception of the
metastatic cascade, even if EMT is certainly not sufficient.
EMT/MET is a normal embryologic reversible program that
allows the conversion of epithelial cells to mesenchymal cells
and inversely during development. Its embryonic implica-
tion, especially in gastrulation, neural crest delamination, and
organ formation and development, is well described [20].
Later, in response to injuries, EMT was shown to be induced
by EGF [21] and used by keratinocytes in healing process [22].
The corner stone of EMT/MET processes is the down-/
upregulation of E-Cadherin (E-Cad), an integral membrane
protein and a component of adherent junctions and an
important mediator of cell-cell adhesion. The CDH1 gene
encodes E-Cad. It can be repressed in twoways, depending on
the effect on the E-cadherin promoter. First, transcriptional
repressors including Snail, Slug, ZEB1, and ZEB2 (zinc finger
proteins) and basic helix-loop-helix (bHLH) such as E47
transcription factor bind directly to E-boxes of the CDH1
promoter region [23–26]. Kruppel-like Factor 8 also represses
E-Cad expression by fixing CDH1 promoter in an E-box
independent way [27]. Second, the bHLH Twist1 factor, E2-
2 factors, and the embryonic transcription factor Goosecoid
indirectly repress the CDH1 transcription [28, 29]. Inter-
estingly, Snail and Twist appear to control positively ZEB1
expression [30].
Many EMT inducers are currently known. Nuclear factor
kappa-B (NF-𝜅B) has a putative binding site on the Snail
promoter, inducing Snail protein and preventing its phos-
phorylation by glycogen synthase kinase-3 (GSK-3) and its
subsequent degradation [31]. It has been shown that tumor
necrosis factor 𝛼 (TNF-𝛼) induces and stabilizes Snail protein
via NF-𝜅B [32]. Transforming growth factor-𝛽 (TGF-𝛽) is
a well-known EMT inducer. The binding of TGF-𝛽 to its
receptor leads to phosphorylation of Smad transcription
factors, which strongly induce Snail and Twist expression,
particularly in presence of high-mobility group protein
HMGA 2 [33]. Protein kinase A (PKA), signal transducer and
activator of transcription 3 (STAT3), and protein kinase D
(PKD) are involved in TGF-𝛽-induced EMT [34, 35].
Local conditions could also modulate the EMT process.
This is the case of hypoxia, a local condition frequently
encountered in the tumor mass. Indeed, during hypoxia,
Notch pathway is activated, resulting in Notch intracellular
domain (NICD) liberation. NICD acts then as a transcription
factor that interacts with DNA-binding protein CSL to
regulate gene expression.NICDparticularly upregulates Snail
expression by direct binding to its promoter [36]. Similarly,
still in hypoxic condition, hypoxia-inducible factor-1 (HIF-1),
potentiated by Notch, is able to stabilize Snail by recruiting
lysyl-oxidase (LOX) [36]. However, HIF-1 can also induce
Twist expression by binding directly to the hypoxia-response
element (HRE) to the Twist promoter sequence [37]. As
another factor was upregulated during hypoxia or inflamma-
tion, vascular-endothelial growth factor or VEGF can induce
Twist and Snail expression by GSK-3 inhibition [38, 39]. The
same regulation of Twist and Snail expression is observed
with EGF as it can particularly act in cooperation with 𝛼5𝛽1
integrin [40]. Sonic-Hedgehog pathway is also related to Snail
expression, probably induced by Gli1 [41] and contributes to
TGF-𝛽-induced EMT [42].HyperactiveWnt signaling occurs
with the progression of different carcinomas and it has been
shown thatWnt stabilizes Snail (and therefore EMT) byGSK-
3B inhibition via Axin-2 [43]. Thus, EMT appears to be the
result of E-Cad repressors activities, especially Snail factors,
in response to inflammation and hypoxic conditions [44],
both features that are met in cancer.
On the other side, another pathway including miRNAs is
well known for its rule in epithelial transition. Bonemorpho-
genetic protein (BMP) pathway, especially via BMP7, induces
miR-205 and miR-200 family of microRNAs, which induce
CDH1 promoter and suppress ZEB1 and ZEB2 expression
[45], and thus promotes MET [46] (Figure 1(e)).
4. EMT-Related Changes
During EMT, epithelial cancer cells, which lean bit by bit
towards the mesenchymal state, loose epithelial features and














































Figure 1: Insights on GBM dissemination process. Both GSC and differentiated cells can undergo EMT in order to invade the brain
parenchyma.This process is regulated by different transcription factors including ZEB, SNAIL, Twist, orNF-𝜅B that are activated upon several
environmental conditions (inflammation, necrosis, and hypoxia) ((a) and (b)). This consequently results in the acquisition of mesenchymal
properties and the expression of ECM degrading enzymes in order to favor tumor spread. This process also sustains intravasation, leading
to systemic dissemination ((c) and (d)). Tumor blood vessels are usually incomplete and leaky, therefore favoring intra-/extravasation (d). In
pathological conditions, the BBB is often disrupted, facilitating GBM cells to jump in the blood flow as well (d).When tumor cells extravasate,
they may either become quiescent or develop metastases. This balance is tightly regulated by environmental conditions and factors including
BMP7 or TGF𝛽2 among many others which may induce either dormancy or a switch toward MET and metastases (e).
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change their protein expression. Hence, it is possible to
characterize the CTC epithelial or mesenchymal phenotype
and specifically the degree of transition. Epithelial cellular
adhesion molecule (EpCAM) [47], cytokeratins [48], zonula
occludens [49], or epithelial splicing regulator 1 (ESPR1) [50]
expression characterize an epithelial phenotype, while N-
Cadherin [51] or Vimentin [52] are expressed in mesenchy-
mal phenotype. Activation of biochemical pathways, such as
Twist-1 or the Akt-PI3K pathway [53], can also be specific
hallmarks of the mesenchymal state. EMT is associated with
the acquisition of several properties that are critical for cancer
dissemination including first repression of the epithelial cell
polarity and proliferation, and second, promotion of cell
resistance to therapy, migration, and invasion [20]. Inversely,
MET promotes cell proliferation and metastasis formation.
E-Cad repressors as well as EMT inducers are involved
in this acquisition. For example, Snail factors induce MMP-
9 expression that is then able to degrade the basement
membrane of blood vessels, a prerequisite step to intrava-
sation. Conversely, some metalloproteases, such as MMP-
3 and MMP-13, can induce EMT [54, 55]. Additionally,
TGF-𝛽 confers resistance to cell death and DNA damage
[56]. In fact, Snail and Slug factors repress proapoptotic
genes expression, in particular PUMA, ATM, and PTEN
that are usually upregulated in the p53-mediated apoptotic
pathway [57]. In the same line, Twist1 and Twist2 were
shown to be overexpressed in a large fraction of human
cancers and are thus able to override the oncogene-induced
premature senescence by abrogating key regulators of the
p53- and Rb-dependent pathways. In epithelial cells, the
oncogenic cooperation between Twist proteins and activated
mitogenic oncoproteins led to complete EMT.Taken together,
these data underlined an unexpected link between early
escape from failsafe programs and the acquisition of invasive
features by cancer cells [58]. EMT is also associated with
chemo- and radio-resistance. Snail indeed inactivates p53-
mediated apoptosis [57], whereas Twist upregulates the ser-
ine/threonine kinase AKT2 [59]. Finally, Kudo-Saito et al.
showed in melanoma that Snail positive tumor cells have
recourse to thrombospondin-1 (TSP-1) in order to impair
dendritic cells, resulting in CD4+ regulatory T cells induc-
tion with immunosuppressive capacity, hence promoting
immunoresistance, immunosuppression, and/or escape of
immune surveillance [60].
Mesenchymal transition also appears to confer or en-
hance stem cell properties by activation of Ras/MAPK path-
way [61] (Figures 1(a) and 1(b)). Snail factors can indeed
promote the Wnt pathway (known for its regulation in self-
renewal and differentiation in stem cells) by E-Cad repression
[62]. ZEB1 and ZEB2 factors downregulate some specific
members of the microRNAs 200 family (miR-200), particu-
larly miR-200c, which targets the polycomb group member
BMI1, an essential regulator of stem-cell renewal, acting as
a repressor of various genes by modulating the chromatin
status [45, 63, 64]. More and more reports highlight the
importance of the miR-200/ZEB feedback loop in determin-
ing epithelial and mesenchymal future of tumor cells [64].
In the same way, Lu et al. used the loop to define three
different states in the continuum between the epithelial and
mesenchymal differentiation: epithelial (high miR-200/low
ZEB), mesenchymal (low miR-200/high ZEB), and partial
EMT (mediummiR-200/medium ZEB) [65].The acquisition
of stem cell properties could explain the possible various
origins of CSC.
No matter the epithelial or mesenchymal state, some cell
markers suggest stemness character in CTC. In breast cancer
for instance, aldehyde dehydrogenase-1 (ALDH1) allows to
detect CTC with CSC properties [53]. The expression of cell
surface markers CD44+/CD24− is also associated with CSC
in breast carcinoma and with CTSC in colon carcinomas
[66]. Gangliosides (GD2, GD3, and GD1A) in breast cancer
and ABC proteins (ABCG2) in lung cancer are also useful
for stemness detection [67, 68], but their utility for CTSC
detection remains uncertain.
5. Dormancy
Tumor cells that are physically separated from the pri-
mary tumor mass and have spread to other anatomical
locations through circulation are called disseminated tumor
cells (DTC). They can be classified as a subgroup of CTC.
Metastasis formation is one option that DTC can follow
but some of them are also able to become quiescent, a
process that is different from senescence and consists in a
nonproliferative state consequent to cell cycle arrest in phase
G0/G1 [69]. Quiescence results from mitogenic signaling
reduction and implies autophagy [70], reduced PI3K-AKT
signaling [71], and activation of stress signaling pathways
[72]. Interestingly, dormancy is significantly influenced by
the microenvironment which can be permissive or restrictive
[73]. In the bone marrow compartment, the presence of
proteins such as GAS6, BMP4, BMP7, and TGF-𝛽2 confers
an adequate environment for dormancy [74–76], whereas
VCAM1, periostin, and extracellular matrix stiffness, with
high density of type I collagen, appear to induce escape
of dormancy [77–79]. Many key players modulate tumor
cells dormancy. Among them, the balance of two prominent
pathways, p38mitogen-activated protein kinase (MAPK) and
extracellular signal-regulated kinase (ERK), might be key
determining factors [75]. A high ratio of ERK/p38 is observed
in metastatic lesions [80], while low ratio of ERK/p38 is
associated with dormancy [81]. In addition, inactivation of
Myc oncogene also leads to senescence [82].
Multiple actors are involved in quiescence process. For
example, fibroblasts express periostin, which recruits Wnt
pathway ligands and increases Wnt signaling in cancer stem
cells, resulting in metastatic colonization [83]. In the bone
marrow stem cell niche, stromal cells, such as osteoblasts, via
TGF-𝛽2, induce low radio of ERK/p-38 and p27 expression,
inhibit CDK4, and in this way induce cancer cell quies-
cence [81]. In the same way, bone morphogenetic protein 7
(BMP-7) binds to BMPR2 that activates p38 and increases
the expression of cell cycle inhibitor p21 and metastasis sup-
pressor gene NDRG1 (N-myc downstream-regulated Gene 1)
[75]. Macrophages, CD4+ and CD8+ T cells, founded in
immune niche, use tumor necrosis factor receptor 1 (TNFR1)
and interferon-𝛾 (IFN-𝛾) in order to induce antiangiogenic
chemokines and prevent proliferation and carcinogenesis
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[84]. More specifically, CD4+ T cells products CXCL9 and
CXCL10, which were described, inhibit angiogenesis [85].
Endothelial cells from bone marrow vascular niches can also
induce quiescence via TSP-1 or perlecan production [78, 86].
Dormancy appears as an important phenomenon in the
cancer relapse as it implies higher resistance against targeted
and conventional therapies, and after long period, sometimes
decades, tumor cells can quit this specific dormancy state
and develop regrowth capacities [87]. A strong link between
dormancy state and tumor stem cells is suspected [88].
Indeed, both dormant tumor cells and tumor stem cells show
a high resistance to current treatments [89, 90] and can
undergo cell cycle arrest in response to different form of
therapy [91, 92]. In glioblastoma, for example, the CSC pool
in tumors is enriched after ionizing radiation. This situation
seems to be in direct consequence with the activation of
DNA damage repair pathways coupled to a reduction of
proliferation and apoptosis via DNA checkpoint kinases [93].
In fact, a subpopulation of CSC is thought to be quiescent
[94]. This view is supported by the fact that dormant cells
and CSC use the same pathways such as Shh, Notch, and
Wnt [95]. The overlap between dormancy state and ability of
tumor-initiation could help to determinate the subpopulation
of tumor cells, which are highly involved in relapses.
6. CTSC and Glioblastoma
6.1. Clinical Evidence. GBM is the most frequent primary
brain tumor and is well known for its poor prognosis despite
multimodal therapies. The rapid relapse of tumor in GBM
patients has indeed been regarded for years as themajor cause
of the lack of GBM spread out of the central nervous system.
However, there are several clinical descriptions of glioblas-
toma metastasis. In 1928, Davis and colleagues described the
first case ever reported of glioblastoma metastasis in a 31-
year-old woman. Since then, a growing body of evidence
has shown the capacity of GBM to spread not only via the
cerebrospinal fluid (CSF) but also via blood or lymphatic
vessels [96, 97] (Figure 1(e)). Interestingly, the number of
GBM metastatic reports increases progressively [98]. This
could be explained by a higher rate of diagnosis not only due
to imaging improvement but also due to the modest but real
increase of patient survival and outcomes. Interestingly, the
incidence of gliomametastases on postmortem examinations
ranges from 6 to 25% for supratentorial tumors [99, 100].
The actual delay between the initial tumor diagnosis and
metastases found in the literature is 1 to 60 months [101].
Thus, clinical evidences allow to asserting the existence of
CTC and DTC in GBM.
6.2. CSC in Glioblastoma. Ignatova et al. first highlighted the
presence of CSC in GBM [102] (Figure 1(a)). Many similar-
ities exist between GSC and normal stem cells in the adult
brain, also termed neural stem cells (NSC).These populations
indeed share particular resemblances in gene expression
and signaling pathways including Notch, Wnt, or TGF-𝛽
signaling [103–105]. CD133 or prominin-1 was proposed as a
biomarker of tumor progression/initiation cells described in
glioblastoma [106], but it appeared later to be insufficient as
CD133-negative cells were also able to initiate tumors [107].
Interestingly, not only Sox2 (a transcription factor) but also
nestin (an intermediate filament protein) and integrin 𝛼6
expression are highly expressed in GSC population [108, 109].
EGFR, whose amplification and mutations are well known in
GBM, also promotes stemness inGBMcells [110]. Although it
is unclearwhetherGSC result from cancerous transformation
of NSC, they have been demonstrated to preferentially locate
in specific niches, more specifically in neurogenic niches,
such as subventricular zone [111]. Evidence also considers
their presence in necrotic niches [112] or in tumor edge niches
[113].
6.3. Defective Brain-Blood Barrier (BBB) and GBM-Circulat-
ing Cells. The blood brain barrier (BBB) consists basically
of endothelial cells connected by tight junctions, surrounded
by astrocytic endfeet with pericytes embedded in the vessel
basal membrane. Nevertheless, neurons and microglia are
also implicated in the BBB cytoarchitecture [114]. In fact, a
double interaction exists between endothelial cells and astro-
cytes, called gliovascular coupling.While endothelial cell can
stimulate astrocytic growth and differentiation, astrocytes
also modulate tight junctions formation and angiogenesis
via the src-suppressed C-kinase substrate (SSeCKS) [115,
116]. Moreover, astrocytic endfeet use aquaporins (AQP) to
maintain the BBB integrity [117].
GBM is the most vascularized tumor in humans [118].
Among others, this can be explained by high levels of vascular
endothelial growth factor (VEGF), particularly in necrotic
core, resulting in endothelial proliferation [119]. Nevertheless,
glioblastoma-induced angiogenesis is imperfect leading to
vessel formation with variable diameter and permeability,
heterogeneous distribution, and basal lamina irregularities
[120] (Figures 1(c) and 1(d)). In 1975, Hirano and Matsui had
already shown fenestrations and tight junctions disruption
in GBM vessels [121]. At the beginning, GBM cells use host
vessels as pathways of invasion [122] and, then, co-opt to these
vessels [123]. These interactions of GBM cells with vessels
become more and more prominent as the disease progresses.
Indeed, new-generated vessels by angiogenesis can support
tumor growth, with a tone controlled by glioma cells [124].
Watkins et al. also showed that glioma cells displace, or even
eliminate, astrocytic endfeet and make direct contacts with
endothelial cells (Figures 1(c) and 1(d)).The result is, first, the
cessation of endothelial/astrocytic interaction and, second,
the breach of BBB, by reduction of tight junctions [124].
Thus, glioblastoma progression seems to tightly associate
with altered BBB permeability, which also constitutes the first
condition to intravasate.
6.4. Glioblastoma Subtypes and EMT:The Mesenchymal Link.
Based on gene expression signatures, four GBM subtypes
have been described: proneural, neural, classical, and mes-
enchymal [125]. In particular, the mesenchymal subtype is
characterized by high expression of CHI3L1 and MET, wild-
type IDH1, mutation/deletion of NF1, Schwann-like features,
and important presence of necrosis/inflammation [125–127].
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This subtype is usually associated with worse prognosis and
most of the time, appears de novo [128, 129]. Fibronectin
and collagen 5𝛼1 are used as markers of mesenchymal GBM
subtype [125]. Some regulators of mesenchymal status have
also been highlighted in this subtype, such as C/EBP-B and
STAT3 transcription factors or the transcriptional coactivator
TAZ [130, 131].
In this context, Bhat and colleagues have recently shown
that microglia are able to induce the mesenchymal sta-
tus via the TNF-𝛼/NF-𝜅B pathway, notably resulting in
radioresistance [132]. Moreover, it has been shown that the
mesenchymal phenotype is associated with higher migratory
capacities of GBM cells. In fact, TGF-𝛽, which is well present
in the GBM environment and secreted by microglia, stromal
and tumor cells [133], is able to induce the mesenchymal
transition, via SMAD2 phosphorylation and recruitment of
ZEB1, especially in GBM with a low or absent expression of
mesenchymal markers [134]. This mesenchymal differentia-
tion can be effectively blocked by A8301, an inhibitor of the
TGF-𝛽 type 1 receptors [134]. Hypoxia, via HIF-1𝛼 and ZEB1,
is also able to induce a mesenchymal switch in GBM [135].
Moreover, Twist overexpression enhances GBM invasion
[136]. Snail is also upregulated in glioma cells compared
to normal brain cells and was shown to promote invasion
[137]. Indeed, its inactivation inhibits glioma progression and
migration [138]. Finally, stromal cell-derived factor (SDF-1)
or CXCL12 and its receptor CXCR4 can induce EMT in GBM
via activation PI3K/Akt and ERK pathways [139]. Interest-
ingly another recent study reported the involvement of the
CXCL12/CXCR4 axis in EMT transition via upregulation of
survivin, a protein involved in apoptosis inhibition [140].
Moreover survivin-mediated EMT was shown to promote
resistance to 𝛾-radiation, suggesting a potential role of EMT
in GBM therapeutic resistance [141].
Asmesenchymal transition is associated with the acquisi-
tion of stem cell properties, hypoxia seems to increase stem-
cell markers in GBM cells, via HIF-1𝛼 and Notch inductions
[142]. Speaking about new properties, mesenchymal transi-
tion in GBM was shown to confer tumor resistance to anti-
VEGF therapy [143].
GBM metastases are not stricto sensu associated with the
mesenchymal subtype. This is no surprise as it has been
demonstrated that different subtypes of GBM can coexist
within the same tumor [144]. Moreover, Ozawa et al. showed
that GBM could derive from a common proneural-like pre-
cursor and that additionalNF1 loss can convert this proneural
subtype to amesenchymal subtype [145].Thus, mesenchymal
transition can be understood as a late phenomenon in GBM,
leading to more aggressive, invasive, and recurrent tumor.
This idea is supported by the fact thatmesenchymal subtype is
frequently found in glioblastoma metastases and recurrences
[146].
6.5. CTSC in Glioblastoma. Recently, CTC have been found
in GBM patients’ blood, highlighted by GFAP detection,
EGFR amplification, or increased telomerase activity [147,
148]. The phenotypes of these CTC in GBM patients were
closed to the mesenchymal or proneural subtypes. However,
recent studies have not found stemness features in those
cells yet, but it does not rule out that some of these CTC
are also indeed true CTSC. Of course, this hypothesis is
sustained by clinical evidences and the existence of GBM
metastases [98]. Recently, Song et al. showed that MMP-
9 is required to cross the BBB, especially the parenchymal
barrier [149]. Interestingly, as Snail also induces MMP-9
expression, the mesenchymal transition therefore seems a
necessary condition to intravasate (Figure 1(c)). Besides, as
dormancy is also a reality in GBM [150], we can speculate
that some of these CTC remain quiescent in other tissue
and could later on initiate relapses. Moreover, circulating
endothelial cells and circulating hematopoietic progenitor
cells also appear to be present in GBM [151]. Interestingly,
GSC have the ability to differentiate into endothelial cells
and show the ability to generate new tumors when grafted
in immunodeficient mice [152] (Figure 1(d)). This reinforces
even more the hypothesis according to which CTSC are an
underrated reality in GBM.
7. Conclusion
Formany years, GBMwas thought to be restricted to the cen-
tral nervous system but a growing body of evidence indicates
that, like many other cancers, hematogenic dissemination
is a reality. CTC characterization is needed to confirm the
presence of CTSC. The question of a possible CTC role
in GBM relapses remains open. We think this is a crucial
question to address as its response could significantly modify
actual therapeutic protocols and have an important impact
on patient outcomes.
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